News & Updates

The patient was a 70-year-old female who presented with a large, fungating left breast mass in September 2022. Although first symptoms were noticed approximately a year earlier, the patient did not seek consultation sooner for fear of cancer diagnosis. Upon examination, the mass occupied the entire left breast. The patient also suffered from shortness of breath and left breast pain. These symptoms worsened, resulting in hospitalization. 

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.